Correction: Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)? - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Is there added predictive value of hepatic and biliary function data from gadoxetate-enhanced MRI for outcomes in primary sclerosing cholangitis (PSC)?

  • By

  • Kumaresan Sandrasegaran

  • Amar S. Shah

  • Cole P. Thompson

  • Channa R. Jayasekera

  • Elizabeth J. Carey

  • Ayana Jain

  • Aubrey N. Silva

  • Suhaas R. Bonkur

  • Anshuman J. Panda

  • Sudhakar K. Venkatesh

  • Alvin C. Silva

  • September 30, 2026

Share

Objective:

The article corrects the name of author Channa R. Jayasekera, which was previously recorded incorrectly as Channa R. Jayasekara.

Approach:
  • : The correction was made to ensure accurate authorship in the published article.
Key Findings:
  • The correction does not alter the findings of the original article but clarifies authorship.
Interpretation:

['Accurate authorship is essential for proper attribution in academic publishing.']

Limitations:
  • The correction does not address any limitations of the original study.
Conclusion:

['The correction serves to maintain the integrity of the authorship in the scientific record.']

Sources:

Original Source(s)

Correction: Do hepatic and biliary functional data from gadoxetate-enhanced MRI add value in predicting outcomes in primary sclerosing cholangitis (PSC)?

  • by Kumaresan Sandrasegaran, Amar S. Shah, Cole P. Thompson, Channa R. Jayasekera, Elizabeth J. Carey, Ayana Jain, Aubrey N. Silva, Suhaas R. Bonkur, Anshuman J. Panda, Sudhakar K. Venkatesh, Alvin C. Silva

  • September 30, 2026

Related Content

Pancreatic arteriovenous malformations as a manifestation of hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease): a systematic review

Toward a Rational Use of Probiotics in Very Preterm Infants

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)